November 14 from 5:30 pm – 7:30 pm PST
Supported By: GSK
- Describe pathophysiological pathways underlying EGPA
- Implement diagnostic strategies to identify patients with EGPA
- Apply evidence-based guidelines to the management of patients with EGPA
Eosinophilic granulomatosis with polyangiitis (EGPA) is the focus of our upcoming Continuing Education (CE) and Continuing Medical Education (CME) symposium. EGPA is a rare systemic necrotizing vasculitis often associated with asthma. This event, led by Dr. Anisha Dua, aims to shed light on critical aspects of the disease, including its pathophysiology and emerging therapeutic options.
EGPA is characterized by vessel inflammation and eosinophilic proliferation, both of which contribute significantly to organ damage. Despite its low incidence and prevalence, EGPA imposes a substantial healthcare burden, with a significant proportion of patients experiencing relapses within five years of initial remission.
The clinical manifestations of EGPA are remarkably diverse, and treatment responses vary widely. To address these challenges, the American College of Rheumatology/Vasculitis Foundation published new treatment guidelines in 2021. Moreover, ongoing research into the pathophysiology of EGPA has identified promising therapeutic targets, particularly eosinophils and B cells.
The primary objective of this educational symposium is to update healthcare professionals, including clinicians, on the latest breakthroughs in understanding EGPA’s underlying mechanisms and the emergence of innovative therapeutic options. By participating, you can earn up to 1.5 credits while gaining valuable insights into managing this complex condition.
Join us on Tuesday, November 14, from 5:30 to 7:30 PM, at the Marriott Marquis in San Diego, CA, for an opportunity to stay at the forefront of EGPA management and provide the best care for your patients.
Our symposium, “EGPA: Highlighting the Patient Journey to Improve the Differential Diagnosis and Accelerate the Initiation of Guideline-Based Care,” will not only enhance your professional growth but also contribute to improving the lives of EGPA patients. This event’s learning objectives encompass a deep dive into the pathophysiological pathways of EGPA, the implementation of diagnostic strategies for identifying EGPA patients, and the application of evidence-based guidelines for optimal patient management. By attending, you will gain a comprehensive understanding of EGPA, from diagnosis to treatment, and be better equipped to make a positive impact on patient outcomes.
Educational grant support for this session is provided by Physicians’ Education Resource and sponsored by GSK. This is not an official program of the American College of Rheumatology.
Anisha Dua, MD, MPH
Anisha Dua, MD, MPH Associate Professor Fellowship Program Director Director of the Vasculitis Center Division of Rheumatology Northwestern University Feinberg School of Medicine Chicago, IL